Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice.
Biomarkers, Pharmacological
/ analysis
Computational Biology
/ methods
Drug Interactions
/ genetics
Feasibility Studies
Genome-Wide Association Study
Genotyping Techniques
/ instrumentation
High-Throughput Nucleotide Sequencing
Humans
Pharmacogenetics
/ instrumentation
Pharmacogenomic Testing
/ instrumentation
Pharmacogenomic Variants
Translational Research, Biomedical
/ instrumentation
Validation Studies as Topic
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
01
05
2020
accepted:
14
07
2020
pubmed:
23
10
2020
medline:
26
10
2021
entrez:
22
10
2020
Statut:
ppublish
Résumé
Interindividual variability in drug efficacy and toxicity is a major challenge in clinical practice. Variations in drug pharmacokinetics (PKs) and pharmacodynamics (PDs) can be, in part, explained by polymorphic variants in genes encoding drug metabolizing enzymes and transporters (absorption, distribution, metabolism, and excretion) or in genes encoding drug receptors. Pharmacogenomics (PGx) has allowed the identification of predictive biomarkers of drug PKs and PDs and the current knowledge of genome-disease and genome-drug interactions offers the opportunity to optimize tailored drug therapy. High-throughput PGx genotyping, from targeted to more comprehensive strategies, allows the identification of PK/PD genotypes to be developed as clinical predictive biomarkers. However, a biomarker needs a robust process of validation followed by clinical-grade assay development and must comply to stringent regulatory guidelines. We here discuss the methodological challenges and the emerging technological tools in PGx biomarker discovery and validation, at the crossroad among molecular genetics, bioinformatics, and clinical medicine.
Identifiants
pubmed: 33089968
doi: 10.1111/cts.12869
pmc: PMC7877857
doi:
Substances chimiques
Biomarkers, Pharmacological
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-119Informations de copyright
© 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Références
Contemp Clin Trials Commun. 2019 Nov 16;16:100493
pubmed: 31788574
Clin Pharmacol Ther. 2019 Aug;106(2):422-431
pubmed: 30739312
High Throughput. 2020 Mar 29;9(2):
pubmed: 32235355
Nat Rev Clin Oncol. 2019 Jun;16(6):386-396
pubmed: 30783251
Nucleic Acids Res. 2019 Jan 8;47(D1):D1005-D1012
pubmed: 30445434
High Throughput. 2018 Dec 18;7(4):
pubmed: 30567415
Immunogenetics. 2017 Aug;69(8-9):617-630
pubmed: 28695285
Nat Genet. 2001 Oct;29(2):233-7
pubmed: 11586306
Clin Biochem. 2016 Nov;49(16-17):1299-1301
pubmed: 27459874
Annu Rev Genomics Hum Genet. 2018 Aug 31;19:73-96
pubmed: 29799802
Front Pharmacol. 2018 Apr 11;9:350
pubmed: 29695966
Pharmacogenet Genomics. 2016 Apr;26(4):161-168
pubmed: 26736087
Oncotarget. 2016 Dec 27;7(52):85895-85904
pubmed: 27825144
Hum Genomics. 2018 May 25;12(1):26
pubmed: 29793534
JRSM Cardiovasc Dis. 2012 Apr 05;1(1):
pubmed: 24175062
AAPS J. 2017 Nov 27;20(1):4
pubmed: 29181807
Genet Med. 2018 Oct;20(10):1122-1130
pubmed: 29446766
J Ovarian Res. 2009 Oct 13;2:14
pubmed: 19825178
PLoS One. 2014 Aug 12;9(8):e100487
pubmed: 25115775
High Throughput. 2018 Oct 26;7(4):
pubmed: 30373182
Oncotarget. 2017 Nov 18;8(64):107558-107564
pubmed: 29296186
J Natl Cancer Inst. 2007 Jul 4;99(13):1036-43
pubmed: 17596577
Expert Rev Mol Diagn. 2018 May;18(5):411-421
pubmed: 29634383